Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy
Status:
Recruiting
Trial end date:
2030-12-01
Target enrollment:
Participant gender:
Summary
This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high
effective in primary central nervous system lymphoma (PCNSL) patients.